Department of Chemistry & Biochemistry University of California, Santa Cruz, CA 95060, USA.
Department of Obstetrics & Gynecology, David Geffen School of Medicine University of California, Los Angeles, CA 90095, USA.
Future Med Chem. 2020 Feb;12(4):325-337. doi: 10.4155/fmc-2019-0266. Epub 2020 Feb 7.
Photo-activatable carbon monoxide (CO)-releasing molecules (photoCORMs), have recently provided help to identify the salutary effects of CO in human pathophysiology. Among them notable is the ability of CO to sensitize chemotherapeutic-resistant cancer cells. Findings from our group have shown CO to mitigate drug resistance in certain cancer cells by the inhibition of cystathionine β-synthase (CBS), a key regulator of redox homeostasis in the cell. Diminution of the antioxidant capacity of cancer cells leads to sensitization to reactive oxygen species-producing drugs like doxorubicin and paclitaxel upon cotreatment with CO as well as in mitigating the drug effects of cisplatin. We hypothesize that the development of CO delivery techniques for coadministration with existing cancer treatment regimens may ultimately improve clinical outcomes in cancer therapy.
光激活一氧化碳(CO)释放分子(photoCORMs)最近为确定 CO 在人类病理生理学中的有益作用提供了帮助。其中值得注意的是 CO 使化疗耐药癌细胞敏感的能力。我们的研究小组发现,CO 通过抑制胱硫醚β-合酶(CBS)来减轻某些癌细胞的耐药性,CBS 是细胞内氧化还原平衡的关键调节剂。癌细胞抗氧化能力的降低导致在与 CO 共同处理时对产生活性氧的药物(如多柔比星和紫杉醇)敏感,并减轻顺铂的药物作用。我们假设开发 CO 输送技术与现有的癌症治疗方案联合使用,最终可能会改善癌症治疗的临床结果。